Table 1. Baseline characteristics of nine included trials for analysis.
| Authors | Year | Phase | Treatment line | Total patients | Treatment regimens | Median age | Duration of anti-HER2 treatment | No. for analysis | Jadad Score |
|---|---|---|---|---|---|---|---|---|---|
| Piccart-Gebhart M.et al | 2016 | III | adjuvant | 8381 | L 750mg daily +T 2mg/kg weekly (loading 4mg/kg)+CT | 51 | 52weeks | 2061 | 3 |
| T 2mg/kg weekly (loading 4mg/kg)-L 750mg daily | 51 | 12weeks-34weeks | 2076 | ||||||
| L 750mg daily +CT | 51 | 52weeks | 2057 | ||||||
| T 2mg/kg weekly (loading 4mg/kg)+CT | 51 | 52weeks | 2076 | ||||||
| Swain S.M. et al(CLEOPATRA) | 2015 | III | metastatic | 808 | P 420mg/kg q.3.w (loading 840mg/kg)+T 6mg/kg q.3.w (loading 8mg/kg) | NR | until progression or unacceptable toxicity | 369 | 5 |
| T 6mg/kg q.3.w (loading 8mg/kg)+docetaxel | NR | until progression or unacceptable toxicity | 335 | ||||||
| Bonnefoi H. et al | 2015 | II | Neoadjuvant | 128 | L 1000mg daily+ CT | 49.9 | 12weeks | 23 | 3 |
| T 2mg/kg weekly (loading 4mg/kg)+CT | 47 | 12weeks | 53 | ||||||
| L1000mg daily +T 2mg/kg weekly (loading 4mg/kg +CT | 49.4 | 12weeks | 52 | ||||||
| Robidoux A. et al (NSABP B-41) | 2013 | III | neoadjuvant | 529 | T 2mg/kg weekly (loading 4mg/kg) | NR | 12weeks | 178 | 3 |
| L 1250mg daily | NR | 12weeks | 173 | ||||||
| T 2mg/kg weekly (loading 4mg/kg)+L 750mg daily | NR | 12weeks | 173 | ||||||
| Guarneri V. et al (CHER-LOB) | 2012 | IIb | neoadjuvant | 121 | T 2mg/kg weekly (loading 4mg/kg)+CT | 50 | 26weeks | 36 | 3 |
| L 1500mg daily+ CT | 49 | 26weeks | 39 | ||||||
| L 100mg daily +T 2mg/kg weekly (loading 4mg/kg)+CT | 49 | 26weeks | 46 | ||||||
| Gianni L. et al (NeoSphere) | 2012 | II | neoadjuvant | 417 | T 6mg/kg q.3.w (loading 8mg/kg)+docetaxel | 50 | 12weeks | 107 | 3 |
| P 420mg/kg q.3.w (loading 840mg/kg)+T 6mg/kg q.3.w (loading 8mg/kg) +docetaxel | 50 | 12weeks | 107 | ||||||
| P 420mg/kg q.3.w (loading 840mg/kg)+T 6mg/kg q.3.w (loading 8mg/kg) | 49 | 12weeks | 108 | ||||||
| P 420mg/kg q.3.w (loading 840mg/kg)+docetaxel | 49 | 12weeks | 94 | ||||||
| Baselga J. et al(CLEOPATRA) | 2012 | III | metastatic | 806 | T 6mg/kg q3w (loading 8 mg/kg)+docetaxel | 54 | until progression or unacceptable toxicity | 396 | 5 |
| P 420mg q.3.w (loading 840mg) +T 6mg/kg q3w (loading 8 mg/kg) +docetaxel | 54 | until progression or unacceptable toxicity | 408 | ||||||
| Baselga J. et al(NeoALTTO) | 2012 | III | Neoadjuvant | 455 | L 1500mg daily+paclitaxel | 50 | 18 weeks | 154 | 3 |
| T 2mg/kg weekly (loading 4mg/kg)+paclitaxel | 49 | 18 weeks | 149 | ||||||
| L1000mg daily+T 2mg/kg (loading 4mg/kg)+paclitaxel | 50 | 18 weeks | 152 | ||||||
| Blackwell K.L. et al | 2010/2012 | III | metastatic | 296 | L1,000mg daily | 51 | until progression or unacceptable toxicity | 146 | 3 |
| L1.000mg daily+ T 2mg/kg weekly (loading 4mg/kg) | 52 | until progression or unacceptable toxicity | 149 |
Abbreviation: L, lapatinib; T, trastuzumab; P, pertuzumab; CT, chemotherapy.